Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients

Table 1

Patients’ baseline characteristics.

	Number; total (36)	Percent (%)
Gender
Female	12	33.3%
Male	24	66.6%
Age, years (mean ± SD); Range	56.3 (±9.8); 27–70
Time from transplant (years)	5.5
Comorbidities
Diabetes	9	25
Hypertension	10	27.7
Dyslipidemia	8	22.2
Others	15	41.6
Indication of liver transplant
HCV-HBV-HCC	1	2.7
HCV	30	83.3
HCV-AIH	1	2.7
HCV-HCC	4	11.1
Donor type
Living	5
Deceased donor	31
HCV RNA at baseline (IU/mL)	8,011,643.0 (±20,301,887.4)
Liver enzymes at baseline (unit/liter)
ALT	69.7 (±59.2)
AST	67.3 (±47.2)
ALP	181.2 (±139.4)
GGT	422.2 (±612)
Primary immunosuppressive medication
Tacrolimus (FK)	36	100
Cyclosporine (CSA)	0	0
Other medications
Prednisone	0
Mycophenolate mofetil	9	25
Biopsy staging:
0	2
1	3
2	13
3	9
4	1
Unknown	5
Regimen
Sofo + peg IFN + RBV for 12 weeks	28	77.7
Sofo + RBV for 24 weeks	8	22.33

Plus-minus values are means ± SD. HCV: hepatitis C virus; HBV: hepatitis C virus; HCC: hepatocellular carcinoma; AIH: autoimmune hepatitis; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transpeptidase. The Metavir fibrosis score (on a scale from F0 to F4, with F0 indicating no fibrosis and F4 fibrosis consistent with compensated cirrhosis) was based on a liver-biopsy specimen reviewed by a central pathologist.